Neoantigen DNA Vaccines Safe, Induce Response in Triple-Negative Breast Cancer
Fourteen of 18 patients had neoantigen-specific T-cell responses; recurrence-free survival was 87.5 percent at 36 months
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.